Companies · Biotechnology
GREAT NECK · Biotechnology
Diligence memoA one-page analyst read on CVUS Ventures, LP — recommendation, valuation, rhythm, risks.→CVUS Ventures, LP looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
CVUS Ventures, LP behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
CVUS Ventures, LP is one of 4291 Biotechnology companies tracked from GREAT NECK. By capital raised it ranks in the long tail (ahead of 16% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 16% of sector peers (real $). Modeled value above 44% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #8 of 131.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Truminim, LLC | Pre-Seed | $1.0M | $55.2M | 3.48× |
| Direct Spinal Therapeutics, Inc. | Pre-Seed | $1.0M | $55.2M | 3.48× |
| Imanis Life Sciences, LLC | Pre-Seed | $1.0M | $55.2M | 3.48× |
| Universal Biosensors Inc | Pre-Seed | $985K | $54.4M | 3.43× |
| One World Lab, Inc. | Pre-Seed | $981K | $54.2M | 3.42× |
| Micropharma Ltd | Pre-Seed | $851K | $47.0M | 2.96× |
| ConverGene LLC | Pre-Seed | $850K | $46.9M | 2.96× |
| CVUS Ventures, LP this company | Pre-Seed | $850K | $46.9M | 2.96× |
| Symbiotic Health, Inc. | Pre-Seed | $850K | $46.9M | 2.96× |
| EternoGen Aesthetics, LLC | Pre-Seed | $939K | $46.3M | 2.92× |
| Genomics USA, Inc. | Pre-Seed | $837K | $46.2M | 2.92× |
| Immunetics, Inc. | Pre-Seed | $1.5M | $46.1M | 2.91× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $850K | 2013-01-15 | $4.7M | $46.9M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
CVUS Ventures, LP is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| ConverGene LLC | Biotechnology | Pre-Seed | $850K | $46.9M | same sector · same stage |
| Gradient Pharmaceuticals, Inc. | Biotechnology | Pre-Seed | $850K | $46.9M | same sector · same stage |
| NeuExCell Therapeutics Inc. | Biotechnology | Pre-Seed | $850K | $46.9M | same sector · same stage |
| Symbiotic Health, Inc. | Biotechnology | Pre-Seed | $850K | $46.9M | same sector · same stage |
| Verifica-BG, Inc. | Biotechnology | Pre-Seed | $850K | $46.9M | same sector · same stage |
| Micropharma Ltd | Biotechnology | Pre-Seed | $851K | $47.0M | same sector · same stage |
| Lab21 Ltd | Biotechnology | Pre-Seed | $838K | $46.3M | same sector · same stage |
| Genomics USA, Inc. | Biotechnology | Pre-Seed | $837K | $46.2M | same sector · same stage |
See where CVUS Ventures, LP sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at CVUS Ventures, LP, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.